• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel Therapeutic Agents in Pediatric Sepsis: Peroxisome Proliferator Receptor γ (PPAR γ) Agonists.

作者信息

Kaplan Jennifer M, Zingarelli Basilia

机构信息

Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

出版信息

Open Inflamm J. 2011 Oct 7;4(Suppl 1-M14):120-124. doi: 10.2174/1875041901104010120.

DOI:10.2174/1875041901104010120
PMID:22259643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3258510/
Abstract
摘要

相似文献

1
Novel Therapeutic Agents in Pediatric Sepsis: Peroxisome Proliferator Receptor γ (PPAR γ) Agonists.小儿脓毒症的新型治疗药物：过氧化物酶体增殖物激活受体γ（PPARγ）激动剂
Open Inflamm J. 2011 Oct 7;4(Suppl 1-M14):120-124. doi: 10.2174/1875041901104010120.
2
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.过氧化物酶体增殖物激活受体 γ 激动剂预防卒中和短暂性脑缺血发作患者复发卒中和其他血管事件。
Cochrane Database Syst Rev. 2023 Jan 10;1(1):CD010693. doi: 10.1002/14651858.CD010693.pub6.
3
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.过氧化物酶体增殖物激活受体γ激动剂用于预防中风或短暂性脑缺血发作患者的复发性中风和其他血管事件。
Cochrane Database Syst Rev. 2017 Dec 2;12(12):CD010693. doi: 10.1002/14651858.CD010693.pub4.
4
hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.肝细胞生长因子是一种下游效应分子，介导过氧化物酶体增殖物激活受体γ激动剂的抗纤维化作用。
J Am Soc Nephrol. 2006 Jan;17(1):54-65. doi: 10.1681/ASN.2005030257. Epub 2005 Nov 16.
5
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.过氧化物酶体增殖物激活受体γ激动剂用于预防中风或短暂性脑缺血发作患者的复发性中风和其他血管事件。
Cochrane Database Syst Rev. 2019 Oct 9;10(10):CD010693. doi: 10.1002/14651858.CD010693.pub5.
6
Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.过氧化物酶体增殖物激活受体γ激动剂在疾病进展中的潜力：超越代谢
Curr Opin Nephrol Hypertens. 2008 May;17(3):282-5. doi: 10.1097/MNH.0b013e3282f9b1c0.
7
Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.过氧化物酶体增殖物激活受体（PPAR）γ激动剂作为心血管疾病的治疗药物：聚焦动脉粥样硬化
Curr Pharm Des. 2017;23(7):1119-1124. doi: 10.2174/1381612823666161118145850.
8
Evolution of peroxisome proliferator-activated receptor agonists.过氧化物酶体增殖物激活受体激动剂的演变
Ann Pharmacother. 2007 Jun;41(6):973-83. doi: 10.1345/aph.1K013. Epub 2007 May 22.
9
Peroxisome proliferator-activated receptor gamma and BRCA1.过氧化物酶体增殖物激活受体 γ 和 BRCA1。
Endocr Relat Cancer. 2019 Feb;26(2):R73-R79. doi: 10.1530/ERC-18-0449.
10
Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases.过氧化物酶体增殖物激活受体γ及其天然激动剂在肾脏疾病治疗中的应用
Front Pharmacol. 2022 Oct 21;13:991059. doi: 10.3389/fphar.2022.991059. eCollection 2022.

引用本文的文献

1
Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan.使用吡格列酮的2型糖尿病脓毒症患者死亡率较低：台湾一项为期15年的全国性倾向评分匹配观察性研究
Emerg Med Int. 2021 Jul 23;2021:4916777. doi: 10.1155/2021/4916777. eCollection 2021.
2
Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism.吡格列酮可能通过促进葡萄糖分解代谢来改善老年小鼠肝脏募集巨噬细胞的吞噬活性。
Innate Immun. 2019 Aug;25(6):356-368. doi: 10.1177/1753425919849620. Epub 2019 May 16.
3
PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma.过氧化物酶体增殖物激活受体：气道炎症的关键调节因子及哮喘潜在治疗靶点
Nucl Receptor Res. 2018;5. doi: 10.11131/2018/101306. Epub 2017 Dec 11.
4
PPAR in Bacterial Infections: A Friend or Foe?过氧化物酶体增殖物激活受体在细菌感染中的作用：是敌是友？
PPAR Res. 2016;2016:7963540. doi: 10.1155/2016/7963540. Epub 2016 Sep 28.
5
PPAR-γ/IL-10 axis inhibits MyD88 expression and ameliorates murine polymicrobial sepsis.PPAR-γ/IL-10 轴抑制 MyD88 表达并改善小鼠多微生物脓毒症。
J Immunol. 2014 Mar 1;192(5):2357-65. doi: 10.4049/jimmunol.1302375. Epub 2014 Jan 31.
6
Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis.吡格列酮通过抑制多微生物脓毒症中的核因子κB来减轻炎症。
Innate Immun. 2014 Jul;20(5):519-28. doi: 10.1177/1753425913501565. Epub 2013 Sep 12.
7
The inflammatory response in sepsis.脓毒症中的炎症反应。
Trends Immunol. 2013 Mar;34(3):129-36. doi: 10.1016/j.it.2012.09.004. Epub 2012 Oct 2.
8
Prophylactic zinc supplementation reduces bacterial load and improves survival in a murine model of sepsis.预防性补锌可降低脓毒症小鼠模型的细菌负荷并提高存活率。
Pediatr Crit Care Med. 2012 Sep;13(5):e323-9. doi: 10.1097/PCC.0b013e31824fbd90.

本文引用的文献

1
FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue.FoxO1单倍剂量不足通过增强脂肪组织中过氧化物酶体增殖物激活受体γ的激活来预防高脂饮食诱导的胰岛素抵抗。
Diabetes. 2009 Jun;58(6):1275-82. doi: 10.2337/db08-1001. Epub 2009 Mar 16.
2
FOXO1 transrepresses peroxisome proliferator-activated receptor gamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes.FOXO1通过反式抑制过氧化物酶体增殖物激活受体γ的反式激活作用，协调脂肪细胞中胰岛素诱导的前馈反应。
J Biol Chem. 2009 May 1;284(18):12188-97. doi: 10.1074/jbc.M808915200. Epub 2009 Feb 26.
3
The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice.噻唑烷二酮类药物环格列酮可减少小鼠肺炎链球菌肺炎期间的细菌生长和早期炎症反应。
Crit Care Med. 2009 Feb;37(2):614-8. doi: 10.1097/CCM.0b013e31819599b6.
4
Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}.脓毒症诱导的中性粒细胞趋化性抑制是由过氧化物酶体增殖物激活受体-γ的激活介导的。
Blood. 2008 Nov 15;112(10):4250-8. doi: 10.1182/blood-2007-12-128967. Epub 2008 Jun 5.
5
Peroxisome proliferator-activated receptor gamma is required for the inhibitory effect of ciglitazone but not 15-deoxy-Delta 12,14-prostaglandin J2 on the NFkappaB pathway in human endothelial cells.过氧化物酶体增殖物激活受体γ是吡格列酮对人内皮细胞中NFκB信号通路产生抑制作用所必需的，但15-脱氧-Δ12,14-前列腺素J2对该信号通路的抑制作用则不需要过氧化物酶体增殖物激活受体γ。
Shock. 2007 Dec;28(6):722-726. doi: 10.1097/SHK.0b013e318055683a.
6
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.罗格列酮对心肌梗死风险及心血管原因所致死亡的影响。
N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21.
7
Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice.胰岛素原C肽对小鼠内毒素休克具有有益作用。
Crit Care Med. 2007 May;35(5):1348-55. doi: 10.1097/01.CCM.0000260245.61343.B3.
8
Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study.罗格列酮治疗可提高患有多囊卵巢综合征的超重女性的血浆脂联素水平，并降低抵抗素水平：一项随机安慰剂对照研究。
Eur J Endocrinol. 2007 Feb;156(2):263-9. doi: 10.1530/eje.1.02331.
9
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma.平行的SUMO化依赖性途径介导肝X受体（LXRs）和过氧化物酶体增殖物激活受体γ（PPARγ）的基因特异性和信号特异性反式抑制。
Mol Cell. 2007 Jan 12;25(1):57-70. doi: 10.1016/j.molcel.2006.11.022.
10
Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis.信号转导及转录激活因子5b促进儿童克罗恩病和小鼠结肠炎的黏膜耐受性。
Am J Pathol. 2006 Dec;169(6):1999-2013. doi: 10.2353/ajpath.2006.060186.